Abstract. T cell costimulation has great therapeutic potential if it can be optimized and controlled. To achieve this, we engineered T cell-activating fusion proteins and immunocytokines that specifically attach to viral antigens of a virusinfected tumor vaccine. We employed the avian Newcastle Disease Virus because this agent is highly efficient for human tumor cell infection, and leads to introduction of viral hemagglutinin-neuraminidase (HN) molecules at the tumor cell surface. Here, we demonstrated the strong potentiation of the T cell stimulatory activity of such a vaccine upon attachment of bispecific or trispecific fusion proteins which bind with one arm to viral HN molecules of the vaccine, and with the other arm either to CD3 (signal 1), to CD28 (costimulatory signal 2a), or to interleukin-2 receptor (costimulatory signal 2b) on T cells. A vaccine with a combination of all three signals triggered the strongest activation of naïve human T cells, thereby inducing the most durable bystander antitumor activity in vitro. Adoptive transfer of such polyclonally activated cells into immunodeficient mice bearing human breast carcinoma caused tumor regression. Furthermore, tumor-reactive memory T cells from draining lymph nodes of carcinoma patients could be efficiently reactivated in a short-term ELISpot assay using an autologous tumor vaccine with optimized signals 1 and 2, but not with a similarly modified vaccine from an unrelated tumor cell line. Our data describe new bioactive molecules which in combination with an established virus-modified tumor vaccine greatly augments the antitumor activity of T cells from healthy donors and cancer patients.
Introduction
The strength of T cell stimulation is determined by numerous parameters including i) the concentration of major histocompatibility complex-restricted antigen on the surface of antigen-presenting cells (APCs) such as dendritic cells (DCs) and its affinity for the T cell receptor (TCR; determining the rate of TCR triggering) (1, 2) , ii) the presence or absence of costimulation (regulating the extent of signal amplification) (3, 4) , such as costimulation via CD28 which is the most prominent costimulatory receptor on T cells (5, 6) , and iii) the duration of the interactions between T cells and DCs (setting the duration of the signalling process) (7, 8) . A low-strength stimulation which may occur with tumor cells can have a negative effect leading to T cell unresponsiveness (anergy) (9) , or apoptosis (10, 11) . However, CD28 engagement drives interleukin-2 (IL-2) production (12, 13) , a cytokine pivotal for T cell growth, survival and cytotoxicity (14) .
We have already reported on three recombinant, monomeric single chain Fv (scFv) fusion proteins (15) (16) (17) . These specially designed molecules provide T cell activation signals by interacting either with the TCR-associated CD3 complex [signal 1, mediated by the bispecific (bs) fusion protein bsHN-CD3], or with the costimulatory molecule CD28 (signal 2a, mediated by bsHN-CD28), or with the IL-2 receptor (signal 2b, mediated by bsHN-IL-2). The trispecific (ts) IL-2 immunocytokine/scFv fusion protein tsHN-IL-2-CD28 described for the first time in this study combines both costimulatory activities (signals 2a and 2b). Such costimulatory signals as well as additional signal 1 may be particularly required in cancer patients whose T cells exhibit a high degree of unresponsiveness to stimulation via tumor-associated antigens (TAAs).
Instead of targeting TAAs which are often heterogeneously expressed within a tumor and between different tumors, our engineered fusion proteins and IL-2 immunocytokines bind to the viral antigen (VA) hemagglutininneuraminidase (HN). This molecule becomes expressed on tumor cells upon infection with the avian paramyxovirus Newcastle Disease Virus (NDV) (18) . The advantages of this concept are i) that NDV has tumor-selective replication properties (19) , ii) that VAs can serve as universal anchor molecules for these fusion proteins and/or immunocytokines, and iii) that NDV provides danger signals thus activating additional innate antitumor immune mechanisms. Human tumor cell infection by NDV is an efficient and safe way to produce an autologous tumor vaccine (first generation ATV-NDV) with pleiotropic immunostimulatory properties (20) . Promising results have already been reported from several clinical phase II trials, including breast cancer (21, 22) , colon
Patients and patient-derived tumor cultures and T cells.
Tumor tissue samples from primary tumors of 4 patients with pathologically confirmed HNSCC [UICC stages II-IV; oropharynx n=1, hypopharynx n=1, larynx n=1, CUP (cancer with unknown primary) n=1; median age at diagnosis 68 years (range 59-74 years)] were taken from the specimens immediately after surgical removal at the Department of Head and Neck Surgery at the University of Heidelberg.
Informed consent from the patients was obtained prior to surgery. Tumor cell cultures were established and maintained as described previously (25) . Histologically metastasis-free draining lymph nodes were also removed from the same patients. They served as a source of autologous T cells. Briefly, lymph nodes were mechanically dissociated in medium and the resulting suspension was passed through a 40-μm cell strainer (BD Falcon, Heidelberg, Germany). T cells were negatively isolated using magnetic beads coated with anti-CD15, anti-CD19 and anti-CD56 mAbs (all from Dynal, Hamburg, Germany) and cryopreserved until used.
Construction and production of recombinant fusion proteins.
The plasmids pERdhfr(αHN-αCD3) (#242) and pERdhfr(αHN-αCD28) (#290) (15) encoding the bispecific fusion proteins bsHN-CD3 and bsHN-CD28, respectively, as well as the plasmid pERdhfr(αHN-IL-2) (#356) encoding the immunocytokine bsHN-IL-2 (17) have been described. The plasmid pERdhfr(αHN-IL-2-αCD28) (#716) encoding the trispecific fusion protein/immunocytokine tsHN-IL-2-CD28 was obtained by cloning the human IL-2 cDNA (derived from plasmid pFc54.7; ATCC, Rockville, MD, USA) between the anti-HN and anti-CD28 scFv portions of plasmid pERdhfr(αHN-αCD28). The fusion proteins were produced and purified by affinity chromatography as described (15) . The protein concentrations were determined with the CBProtein Assay™ Reagent (Calbiochem, Schwalbach, Germany) and using bovine serum albumin (BSA) as reference protein.
In order to be able to compare the fusion proteins with each other, they were separately titrated for their binding to Ltk.HN cells using FACS analysis. An arbitrary HN activity of 10,000 U/ml was attributed to a protein dilution which stained 50% of the Ltk.HN cells. The IL-2 activity of the fusion proteins was assessed using the IL-2-dependent cell line CTLL. A summary of the protein characteristics is provided in Table I . Their binding specificities to NDVinfected MCF-7 tumor vaccine cells and activated human T cells are outlined in Fig. 1 .
NDV.
For virus infection, the avirulent, non-lytic NDV strains Ulster and LaSota were used. Origin, maintenance, purification, and quantitation have been described (20) . Unless otherwise noted, NDV Ulster was used throughout the experiments.
Isolation of peripheral blood mononuclear cells (PBMC) and PBMC subsets.
Human PBMC were isolated via FicollPaque (Amersham Biosciences) centrifugation from buffy coats or from fresh heparinized blood of healthy donors. Natural killer (NK) cell, total T cell, CD4 + T cell and CD8 + T cell subsets were magnetically purified from PBMC with the use of the corresponding Dynal Negative Isolation Kit (Hamburg, Germany). Naïve T cells were obtained by adding 1 μg anti-CD45RO mAb per 10 7 cells (UCHL1; BD Pharmingen, Heidelberg, Germany) to the antibody cocktail of the T Cell Negative Isolation Kit to additionally remove memory T cells. Monocytes were enriched via adherence to a plastic surface. Briefly, PBMC were incubated for 2 h at 37˚C in cell culture flasks. Then, the supernatant was removed (nonadherent PBMC subset) and the remaining attached cells were washed twice before they were detached by scraping (adherent PBMC subset).
Vaccine preparation. MCF-7 or Ltk.wt cells were γ-irradiated with 200 or 100 Gy (Gammacell 1000; Atomic Energy of Canada), respectively and then modified for 1 h at 37˚C with 100 hemagglutination units (HU) NDV Ulster or LaSota per 10 7 cells (VN: MCF-7-NDV or Ltk.wt-NDV), as described (20) . In some cases, the HN-expressing Ltk.HN cells (γ-irradiated with 100 Gy) were used as stimulator cells as a vaccine surrogate. Irradiated MCF-7 cells were infected with NDV and the fusion proteins were bound to the cells for 30 min on ice. The cells were washed and the proteins were detected with anti-His 6 -tag (for all except bsHN-CD28) or anti-E-tag (for bsHN-CD28) mAbs, followed by PE-labelled goat F(ab') 2 anti-mouse antibody. Finally, the cells were analyzed by FACS. In the histogram overlays, dotted and dashed lines reflect the binding of the fusion proteins after 1 h (virus adsorption to the tumor cell membrane) and 24 h (virus replication) of virus infection, respectively. The NDV HN-specific mAb HN.B served as a positive control. (B) Purified T cells (TCs) were preactivated for 48 h by coincubation with autologous dendritic cells (DCs), generated as described (28) , in the presence of SEB (1 μg/ml) at a TC:DC ratio of 5:1. Fusion proteins were bound and detected as in (A). Gray histograms represent cells stained with secondary antibodies only (without fusion proteins: negative controls). IL-2R, IL-2 receptor. Table I . Summary of the characteristics of the purified fusion proteins.
Protein structure Protein amount (μg/ml) HN activity (U/ml) IL-2 activity (U/ml) 
a Each fusion protein (plasmid reference no. and protein structure are provided) is characterized by its protein concentration, its HN activity, and its IL-2 activity (determined as described in Materials and methods). n.d, not determined.
-
of cell divisions) were determined by comparing the CFSE dilution with naïve T cells stimulated by vaccine cells only.
Tumor neutralization assay (TNA).
The assay system was adjusted from Haas et al (16) . The experimental tests were performed in 96-well microtiter plates (in triplicates). For effector cell passages, the setup was scaled up to a 6-well TNA system (in duplicates). Briefly, using 96-or 6-well plates, 3x10 3 or 5x10 4 live MCF-7 tumor target cells, respectively, were seeded and incubated for 4 h until they became adherent. Effector cells (derived from healthy donors) were either freshly isolated, non-activated total PBMC (Fig. 4) , purified subsets from PBMC (Figs. 4A and 5B), or naïve human T cells that had been preactivated in an MLTC using Ltk.HN as a vaccine surrogate (Fig. 5A) ; in the first two cases, the effector cells were added to the wells at an effector to target cell ratio of 5:1 (i.e. 1.5x10 4 cells per well). When using non-activated responder cells (Figs. 4 and 5B), 10 3 or 1.67x10 4 MCF-7-NDV vaccine cells were used for the 96-or 6-well TNA system, respectively. Subsequently, the fusion proteins were added at the indicated concentrations. Then, the plates were incubated until the tumor monolayer in the control wells became confluent (6-7 days for the first passage, and 3 days for the following passages or when MLTC-preactivated cells were used). Finally, the surviving tumor cells in the 96-well TNA test plates were quantified and the tumor growth inhibition was calculated from triplicates as described (16) . For passages, the effector cells from the 6-well plates were harvested, washed twice, and added onto fresh MCF-7 monolayer targets (2.5x10 4 or 4.2x10 5 cells per well for a 96-or 6-well TNA, respectively).
Interferon-γ (IFN-γ) ELISpot.
To determine systemic tumorreactive T cell immunity in HNSCC patients, we performed a short-term ELISpot (enzyme-linked immunospot) assay, as described (28) . It was modified insofar as purified patientderived T cells isolated from draining lymph nodes were not stimulated with tumor antigen-presenting dendritic cells, but with autologous tumor vaccine cells loaded with fusion proteins. Briefly, tumor vaccine cells were prepared by γ-irradiation (200 Gy) and NDV LaSota infection (100 HU per 10 7 cells), and loaded with the bispecific fusion proteins bsHN-CD3 (3 μg per 10 6 cells) and/or bsHN-C28 (6 μg per 10 6 cells). Loaded vaccine cells (2x10 4 ) were coincubated for 40 h with 2x10 5 autologous T cells in IP-ELISpot plates (Millipore, Molsheim, France) coated with an anti-IFN-γ mAb (1-D1K; Mabtech, Hamburg, Germany) and analyzed for cytokine secretion according to the manufacturer's protocol. Spot-forming cells were quantified using an Axioplan 2 Imaging Microscope (Zeiss, Oberkochen, Germany) and the KS-ELISpot software (Zeiss Vision, Göttingen, Germany). All tests were performed in triplicates. The allogeneic promonocytic lymphoma cell line U937 was used as a specificity control instead of autologous tumor cells. 10 7 ) were injected s.c. into NOD/SCID mice (n=8 per group). The mice were kept until the tumors reached a diameter of 6-8 mm. Then, at intervals of 3 days (at days 1, 4, and 7), mice were treated thrice by an i.p. injection of 10 7 PBMC from a healthy, HLA-A2-positive donor (thereby matching the HLA-A2-positive MCF-7 tumor cell line). The PBMC were preactivated ex vivo for 3 days either with MCF-7-NDV tumor vaccine loaded with the bispecific fusion proteins bsHN-CD3 (10 μg per 10 7 cells) and bsHN-CD28 (30 μg per 10 7 cells) (full activation), or with MCF-7-NDV tumor vaccine only. A third group consisted of mice receiving i.p. the supernatant from fully activated PBMC. PBS-treated mice served as a negative control. Tumor growth was assessed over time at intervals of 6-14 days.
Assay for immunotherapeutic capacity in vivo. MCF-7 tumor cells (
Immunohistochemistry. At the end of the therapy experiment, tumor tissue samples from treated mice were removed and shock-frozen in liquid nitrogen. To detect human lymphocyte infiltration, 5-μm cryosections were cut and stained with murine anti-human mAbs against CD4, CD8, CD69 and CD45RO (all from Dako, Hamburg, Germany). Visualization was performed using a horseradish peroxidase-conjugated polyclonal goat anti-mouse immunoglobulin and 3-amino-9-ethylcarbazole as substrate (TissueGnost AEC; Merck, Darmstadt, Germany). Sections were counterstained with hematoxylin to reveal histological structures.
Statistical analysis. Differences between two means were calculated in Excel software with the two-tailed Student's t-test. They were considered significant at a p-value ≤0.05. For the in vivo experiment, analysis of variance (ANOVA) was applied. p-values from multiple testings were adjusted according to Bonferroni-Holm.
Results

T cell costimulatory activity of anti-CD28-and IL-2-containing fusion proteins.
The two proteins bsHN-CD28 and tsHN-IL-2-CD28 were compared for costimulatory activity based on equal units of binding to viral HN. Costimulatory activity was tested in a T cell proliferation assay ([ 3 H]-TdR incorporation) in which purified T cells from human peripheral blood were coincubated with γ-irradiated Ltk.HN cells in the presence of different concentrations of these proteins and of a suboptimal concentration of bsHN-CD3 (signal 1) (Fig. 2A) . bsHN-CD28 (signal 2a; Fig. 2B ) and tsHN-IL-2-CD28 (signal 2a plus 2b: 2a-2b; Fig. 2C ) showed both costimulatory activity. There was no costimulatory effect with Ltk cells expressing no HN protein (Ltk.wt) for bsHN-CD28 (Fig. 2B ) while tsHN-IL-2-CD28 caused a slight dose-dependent T cell proliferation (Fig. 2C) resulting from the IL-2 which can act both in a cell-bound and soluble form.
To exclude a contribution of memory T cells in the functional assay, we next studied the activation of purified naïve T cells by a vaccine modified with the various fusion proteins. We labelled these highly pure naïve T cells, which also did not contain T regulatory cells (data not shown), with CFSE and quantified the numbers of cell divisions after 5 and 7 days by FACS analysis (Fig. 2D) . While the majority of naïve T cells in the controls (stimulated with either suboptimal signal 1 alone, or signals 2a or 2b alone, or signal 2a-2b alone) underwent no divisions, the majority of cells that were provided with signal 1 in combination with either signal 2a, 2b or 2a-2b underwent one, two or even three cell divisions. These quantitative data on T cell proliferation demonstrate i) that the vaccine-bound fusion proteins containing anti-CD28 scFv and/or IL-2 in combination with suboptimal signal 1 activated naïve T cells, and ii) that bsHN-IL-2 (signal 2b) was at least as costimulatory in this assay as bsHN-CD28 (signal 2a).
Induction of T cell activation markers and effector function by NDV tumor vaccine presenting anti-CD28-and IL-2-containing fusion proteins.
T cell activation was further assessed by upregulation of activation markers and effector proteins. After coincubation of purified naïve T cells for 6 days with γ-irradiated Ltk.HN cells in the presence of the various fusion proteins, we measured the upregulation of CD25, the α-chain of the IL-2 receptor, and CD45RO, a marker for the transition of naïve to memory cells (Fig. 3A) . The classical combination of anti-CD3 in a suboptimal dose with anti-CD28 at an optimal concentration (40.5 U) induced an upregulation of both markers in ~20% of the T cells. Notably, the new immunocytokines containing IL-2 (signal 2b) induced a much stronger costimulatory effect (strictly depending on signal 1) so that at least twice as many T cells coexpressed CD25 and CD45RO. The superior costimulatory activity was observed at all doses of the IL-2-mediated costimulus. A reduced costimulatory activity noted at the highest concentration was possibly due to competition with the bsHN-CD3 reagent that provided signal 1.
Furthermore, to determine whether the IL-2 immunocytokine-modified vaccine could also activate effector functions in naïve T cells, we tested by FACS analysis the upregulation of CD107a, a lysosomal associated membrane protein (LAMP-1) which becomes expressed at the outside of the plasma membrane when CD8 + T cells exert cytotoxic function (29) . Fig. 3B shows a dose-dependent upregulation of CD107a on activated CD8 + T cells (CD8/CD25 doublepositive cells). At the optimal amount of costimulus (40.5 U), only ~40% of the cells having received the anti-CD28 costimulus became cytotoxic while ~80% were cytotoxic after costimulation with the new IL-2 immunocytokines.
Since all experiments so far had been performed with stable transfectants, we had to ensure that the results could be transferred to a virus-infected tumor vaccine. To this end, and also to investigate a possible relationship between the costimulatory signals 2a and 2b, we labelled purified naïve T cells with CFSE and coincubated them with an MCF-7-NDV tumor vaccine for 6 days. All experimental groups received a suboptimal amount of bsHN-CD3 along with three different doses of bsHN-CD28 and bsHN-IL-2 in all possible combinations. T cell activation was assessed via FACS analysis and was expressed as the percentage of dividing CD25/CD45RO double positive cells (Fig. 3C ). There was a plateau of 20-25% activated cells as long as one of the two costimuli was added in a sufficient amount. Thus, a low dose of one costimulus could be compensated by a higher dose of the second one. This suggests a possible cross-talk between costimulatory signals mediated via IL-2 receptor and CD28.
Antitumor activity induced in PBMC and PBMC subsets by NDV-infected tumor vaccine with optimized costimulation.
The main purpose of a tumor vaccine is the activation of immune antitumor activity. To evaluate such activity in vitro, we recently established a tumor neutralization assay (TNA) which is basically a mixed lymphocyte tumor cell culture (MLTC) performed on top of an adherent tumor cell monolayer as a bystander target. Coincubation of PBMC for 5-7 days with the modified vaccine cells resulted in the generation of cytotoxic effector function and in the release of a variety of cytokines (16) . The surviving tumor cells were quantified by the live cell staining reagent MTS. Fig. 4A shows the results of such assays when performed with total PBMC or with different PBMC subsets. NDV infection of the tumor vaccine was sufficient to activate NK cells to exert bystander antitumor effects. A significant increase in tumor growth inhibition was always observed with a tumor vaccine presenting signals 1 and 2a in subsets containing T cells. Purified CD8 + as well as purified CD4 + T cells exerted strong bystander antitumor activity upon costimulation while this was not observed with purified NK cells.
Optimization of the costimulation using IL-2 immunocytokines can further augment the antitumor activity in PBMC (Fig. 4B ). Fig. 4B shows a stepwise increase in the bystander tumor growth inhibition upon tumor vaccine modification. The first effect is due to NDV infection (NDV effect). The second effect is due to the vaccine-bound costimulatory IL-2 (IL-2 effect). Finally, a combination of IL-2-and anti-CD28-mediated signals (anti-CD28 + IL-2 effect) resulted in the strongest antitumor activity. Notably, in the absence of NDV infection, the fusion proteins did not augment the antitumor effect even when used at optimal concentrations.
Antitumor effector activity of T cells activated by NDVinfected tumor vaccine with optimized costimulation and its duration after serial passage.
Since the TNA assay (Fig. 4B) does not allow for distinguishing between the steps of T cell activation and effector function, we next analyzed the Hatched bars indicate T cells activated in the presence of suboptimal bsHN-CD3 alone (negative controls). For serial passages, the same conditions were performed in parallel using a 6-well TNA format with identical protein concentrations (TNA passage plates). After 7 days, the TNA test plates were developed as described in Materials and methods. The cells from the TNA passage plates were harvested, washed and transferred for another 3 days onto fresh MCF-7 monolayers, either in 96-well TNA test plates (passage 1), or in 6-well TNA passage plates for another round (passage 2). The mean growth inhibition of triplicate cultures ± SD is shown; * p<0.0021. generated effector function separately. MLTCs were first carried out for 6 days with naïve T cells in the absence of tumor monolayers, using γ-irradiated Ltk.HN vaccine cells and the indicated HN-specific fusion proteins (Fig. 5A : MLTC combinations). Upon transfer onto MCF-7 human breast carcinoma cells, within 3 days the generated effector T cells exerted the indicated tumor growth inhibition ( Fig. 5A ; TNA result). There was a significantly higher antitumor effector activity in cultures in which the costimulus was provided by IL-2 or by IL-2 plus anti-CD28 in comparison to anti-CD28 alone. This further supports and extends our previous results and conclusions. Another important aspect of T cell effector activity relates to its duration. To test this, we repeatedly transferred purified T cells that were activated only once by MLTC onto fresh tumor monolayers and followed destruction of the latter as shown in Fig. 5B . The results revealed a much longer duration of bystander antitumor activity in T cells activated by the signals 1, 2a and 2b together (bsHN-CD3 plus tsHN-IL-2-CD28) than in T cells activated by only two signals. Expressed quantitatively, a simultaneous introduction of costimulatory signals via CD28 (signal 2a) and IL-2 receptor (signal 2b) led to a 20-40% increased bystander antitumor activity in passage 1 (days 7-10) and passage 2 (days 10-13) when compared to a tumor vaccine with only one costimulatory signal.
Reactivation of memory T cells from cancer patients by NDV-infected autologous tumor vaccine loaded with bsHN-CD3 and bsHN-CD28.
All experiments so far were performed with immune cells from normal healthy donors. Therefore, it was important to test if the modified vaccine would also be capable of (re)activating T cells from cancer patients. For that purpose, we applied a modified short-term IFN-γ ELISpot assay which we previously established for reactivation of cancer-reactive memory T cells (28) . From four different tumor patients, operated on for HNSCC, primary tumor cells were expanded, were prepared as a vaccine (NDV infection and loading with the fusion proteins) and were finally combined with autologous T cells isolated from draining lymph nodes. The data from Fig. 6 show a strong IFN-γ secretion only in that group where T cells received both anti-CD3 and anti-CD28 signals. Specificity was demonstrated by using the human promonocytic lymphoma cell line U937 which could not (re)activate T cells under the same conditions.
In vivo therapeutic efficiency of human PBMC preactivated in vitro by NDV-infected tumor vaccine loaded with bsHN-CD3 and bsHN-CD28.
To study the immunotherapeutic effects of vaccine-activated PBMC in vivo, we recently established an NOD/SCID mouse model which allows outgrowth of the MCF-7 breast cancer cell line (28) . For therapy, PBMC from a healthy donor were preactivated with an MCF-7-NDV tumor vaccine (VN) loaded or not with bsHN-CD3 and bsHN-CD28, followed by i.p. injections into mice with established MCF-7 xenotransplants (Fig. 7A) . PBS-treated control mice showed progressive tumor growth, as did tumors from mice treated with PBMC preactivated with MCF-7-NDV tumor vaccine only. The tumors of mice, however, treated with fully activated PBMC started to regress 51 days after adoptive cell transfer. Notably, treatment of mice with supernatants from fully activated PBMC cultures, did not lead to tumor regression. Immunohistochemical stainings of tumors that underwent regression revealed a heavy infiltration by both human CD4 + and CD8 + T cells, a certain percentage of which were activated (CD69 positive) and exhibited a memory phenotype (CD45RO positive). In contrast, tumor sections from PBS-treated controls revealed no tumorinfiltrating T cells (Fig. 7B) .
Discussion
We demonstrated here strong potentiation of T cell antitumor activity by the use of T cell-activating bispecific and trispecific fusion proteins and IL-2 immunocytokines which Figure 6 . Memory T cells of HNSCC patients can be specifically reactivated by a modified autologous tumor cell vaccine. In a short-term IFN-γ ELISpot assay, purified T cells isolated from draining lymph nodes (LN) of HNSCC patients were coincubated with the indicated autologous vaccine formulations (tumor) (n=4). For specificity control, the irrelevant human promonocytic cell line U937 (U937) was used to activate patient T cells. The frequency of IFN-γ-secreting T cells was determined as described in Materials and methods. Each boxplot column represents the pooled median, 25% and 75% (bars 5% and 95%) quartile counts of IFN-γ-secreting T cells from the four different patients. V, non-infected γ-irradiated tumor vaccine; VN, NDV-infected γ-irradiated tumor vaccine.
* p<0.005.
were attached to an NDV-infected human tumor vaccine. The extent of the T cell-mediated tumor growth suppression particularly depended on the optimization of the costimulatory signals (anti-CD28 and IL-2). We furthermore demonstrated that human effector T cells, which were preactivated by such a modified tumor vaccine, could be induced for in vivo antitumor activity against established tumors. Since many tumors lack appropriate costimulatory ligands for T cell activation (5), numerous studies have aimed at introducing costimulatory molecules into tumor cells via gene transfer, including the CD28 ligands CD80 (B7-1) and CD86 (B7-2). Using established tumor cell lines which were modified by electroporation (30, 31) or by recombinant viral vector transfection (32) (33) (34) to express the costimulatory molecules, this strategy often resulted in impressive tumor regression rates and antitumor immunity in various murine tumor models. A clinical application of this approach, however, is generally impeded by technical hurdles and low transfection efficiencies. For instance, in one study, from 116 malignant gliomas only three patients could be vaccinated by a retrovirally transduced autologous tumor vaccine (35) . For comparison, in our glioblastoma study, the efficiency of ATV-NDV production was 90% (26) , which underlines the feasibility and reproducibility of our autologous tumor vaccine preparation. Furthermore, we showed previously (15, 16) , and confirmed here, that all of our bispecific and trispecific fusion proteins/immunocytokines do not trigger T cells by themselves, but only when attached to HN-expressing transfectants or NDV-infected tumor vaccine cells, thus demonstrating specificity and safety. Instead of introducing the CD28 ligands CD80 or CD86 into the tumor vaccine, we preferred the use of anti-CD28 scFv binding sites, since in contrast to CD80 and CD86 the latter bind to costimulatory CD28, but not to coinhibitory cytotoxic T lymphocyte antigen-4 (CTLA-4) Figure 7 . PBMC preactivated by MCF-7-NDV vaccine loaded with bsHN-CD3 and bsHN-CD28 can cause tumor regression upon adoptive transfer to human tumor xenotransplanted mice. (A) Tumor growth curves. MCF-7 tumor cells were s.c. injected into NOD/SCID mice (n=8 per group). The mice were kept until palpable tumors were established (6-8 mm in diameter). Then, at days 1, 4, and 7 the mice were treated by i.p. injection of 10 7 PBMC which were preactivated ex vivo for 3 days under the indicated conditions. Tumor growth was monitored over time. VN, NDV-infected γ-irradiated MCF-7 tumor vaccine. * p<0.05. ** p<0.005. (B) Representative immunohistochemistry images of tumor tissue sections in PBS-treated control mice (right-hand images) and in mice treated with PBMC preactivated with MCF-7-NDV, bsHN-CD3 and bsHN-CD28 (left-hand images). The sections were stained with mAbs against the human antigens CD4, CD8, CD69 and CD45RO, respectively. Scale bar, 100 μm. molecules on T cells (36) . Therefore, it can be assumed that concomitant administration of CTLA-4 blocking reagents to augment T cell-mediated antitumor immunity (37-39) would not be necessary.
The present study for the first time introduces HN-specific IL-2 immunocytokines, recombinant antibody-cytokine fusion proteins, which can target tumors and achieve high cytokine concentrations in the tumor microenvironment. We chose the cytokine IL-2 because IL-2 immunocytokines were shown, in syngeneic mouse tumor models, to be capable of eradicating established pulmonary and hepatic metastases of melanoma (40) and colon carcinoma (41) . Our study reveals that in the presence of a TCR/CD3-mediated signal 1, the vaccine-bound IL-2 immunocytokine bsHN-IL-2 provided a T cell costimulatory signal which led to the induction of naïve T cell proliferation, upregulation of activation and memory markers and generation of antitumor cytotoxic effector cells. Since in the absence of signal 1, bsHN-IL-2 alone did not induce (de novo naïve) T cell activation, tumor vaccine-bound IL-2 can be considered as a costimulus, similar to anti-CD28. To the best of our knowledge, this fact has not been previously described. Further investigations of anti-CD28-and IL-2 receptor-mediated costimulation during naïve T cell activation are in progress. Most important was the finding that a single human T cell stimulation with a vaccine providing signal 1 and costimulatory signals via CD28 and IL-2 receptor induced the strongest (Fig. 4B ) and most durable (Fig. 5B) antitumor effect. Without the IL-2-mediated signal the duration of this bystander antitumor activity was much shorter. These findings are in accord with recent data demonstrating that IL-2 signals during priming endow CD8 + T cells with a memory program of secondary expansion capacity (42) . Additionally, they corroborate results from other groups who provide evidence that a combination of two [anti-CD28/anti-4-1BB (43)] or even three [B7-1/ICAM-1/LFA-3 (44)] costimuli synergize and induce T cell activation to a far greater extent than any one of the costimulatory molecule(s) alone.
In this study, using NOD/SCID mice xenotransplanted with the human breast carcinoma cell line MCF-7, we also demonstrated for the first time the in vivo antitumor activity of human effector T cells activated by NDV-infected MCF-7 tumor vaccine cells and optimized anti-CD3/anti-CD28 signals (fully activated PBMC). That only the tumors from mice treated with the fully activated PBMC eventually regressed and became heavily infiltrated by T cells points at a cellular, rather than humoral immune response in which both CD8 + and CD4 + T cells seem to be involved (45, 46) . This observation is supported by two facts. First, neither tumors of mice treated with tumor vaccine-activated PBMC, nor tumors of mice treated with supernatants from fully activated PBMC exhibited tumor regression. Second, tumor-infiltrating cells from both T cell subsets showed strong expression of the activation marker CD69 and the memory marker CD45RO, reflecting our in vitro data. It is noteworthy that we used polyclonally (anti-CD3/anti-CD28) activated T cells (as a PBMC subset) from a healthy donor. These did not contain a strongly enriched fraction of TAA-specific T cells, as used by others for adoptive immunotherapy (47) (48) (49) . Nevertheless, in spite of the xenograft human-into-mouse transfer system, we observed a therapeutic effect but no signs of graft-versushost disease (GvHD) (data not shown). This is in line with our previous in vitro observations where we revealed a remarkable selectivity of such polyclonally activated T cells for tumor verus non-tumor cell lines (16) . The reason for this selectivity is still unclear. It may have to do with the fact that the T cells were activated with anti-CD3/anti-CD28 signals in the presence of tumor vaccine cells and danger signals.
Such an assumption is supported by our ELISpot results. The activation of naïve T cells by the modified vaccine required 5-7 days. In contrast, activation of memory T cells is known to be shorter (50) . Using a short-term memory assay, we were able to stimulate a significant immune response in patient-derived T cells coincubated with an autologous, NDV-infected tumor vaccine optimized with anti-CD3/anti-CD28 signals. This finding points towards an induction of a specific memory T cell response, since i) our short-term assay (~48 h) detects memory, rather than de novo naïve T cell activation (28) , and ii) an unrelated tumor cell line, U937, lacking TAA from HNSCC, did not provoke any significant T cell response upon similar modification. We verified that U937 cells could indeed be infected efficiently by NDV and could be modified by both bsHN-CD3 and bsHN-CD28 (data not shown). We therefore propose that the specific short-term ELISpot response required recognition of TAA from HNSCC patients and amplification by T cellactivating signals 1 and 2a.
In order to improve the efficacy of immunotherapeutical approaches, there is a need to maximize the antitumor response, including the attack of tumor escape variants that lack the ability to present a given TAA. The promising results obtained here with our second generation tumor vaccine demonstrate that it has a dual activity: it can activate specific T cells from cancer patients (most likely TAA-specific memory T cells) and can generate antitumor activity from naïve T cells. This dual activity is particularly vital for patients whose T cells exhibit a high degree of unresponsiveness to stimulation via TAA. Also, in comparison to genetically modified tumor vaccines, our modular approach of attachment of fusion proteins and/or IL-2 immunocytokines has the advantage of easy qualitative and quantitative adjustment of the T cell-activating signals to the requirements of the patient. Finally, a clinical phase I/II trial using autologous tumor vaccine cells (ATV-NDV) modified by the fusion proteins bsHN-CD3 and bsHN-CD28 has recently been initiated, in order to validate our findings in colorectal cancer patients.
